RxDoctor Payments Data

Enrique de la Torre, MD

Internal Medicine · Miami, FLNPI 1306054515

Payments from drug & device makers

$523,578in general payments, 2019–2025

Across 89 payments — averaging $5882.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$350K
  • Sanofi$118K
  • Sanofi US Services Inc.$37K
  • Genentech, Inc.$14K
  • Chiesi USA, Inc.$5K
  • Amgen$44
  • plus $77 from 3 others
$166in research payments, 2019–2025

Across 2 payments — averaging $83.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$116
  • Sanofi US Services Inc.$50

What the payments were for

  • Travel & lodging$39477%
  • Food & beverage$12123%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$523,578 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$16,198
Medicare patients
25
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$120,322
TrulicityDulaglutide23$29,331
EntrestoSacubitril/Valsartan34$28,250
TivicayDolutegravir Sodium13$27,485
DescovyEmtricitabine/Tenofov Alafenam13$26,813
FarxigaDapagliflozin Propanediol34$21,589
JardianceEmpagliflozin29$20,437
JanuviaSitagliptin Phosphate32$19,572
OzempicSemaglutide19$17,786
XareltoRivaroxaban20$16,510
MounjaroTirzepatide16$16,418
Aripiprazole18$16,334
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$12,857
Xigduo XrDapaglifloz Propaned/Metformin12$6,692
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$5,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$120,322189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →